Skip to Main Content

Over the past 20 years, Yale inventions have led to the creation of nearly 60 companies in the New Haven region that have attracted more than $1 billion of professional venture capital investment and have created over 1,400 jobs in the region. Many of these local companies are focused on oncology drug development based on science from Yale Cancer Center members, including:


Arvinas Logo Craig Crews, PhD
Research Program: Developmental Therapeutics

Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases.
https://arvinas.com/
CaroGen Logo John Rose, PhD
Research Program: Virus and Other Infection-associated Cancers

CaroGen Corporation is an emerging biopharmaceutical company that has developed viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites.
https://carogencorp.com/
Cybrexa Logo Peter Glazer, MD, PhD
Research Program: Radiobiology & Radiotherapy
Ranjit Bindra, MD, PhD
Research Program: Radiobiology & Radiotherapy

Cybrexa Therapeutics is an oncology-focused biotechnology company developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.
https://cybrexa.com/
HistoRX logo David Rimm, MD, PhD
Research Program: Signal Transduction

HistoRx is developing novel diagnostic solutions to enable new approaches to individualized patient care.
Immunova logo

Tarek Fahmy, PhD
Research Program: Developmental Therapeutics

Immunova Pharmaceuticals has a proprietary Nanolipogel™ platform to deliver desired combinations of drugs in nanoparticle formulations to the disease microenvironment.
http://www.immunova.net/

Isoplexis Logo

Rong Fan, PhD
Research Program: Signal Transduction

IsoPlexis is transforming precision oncology in cell and cancer immunotherapy by defining the complete function of each cell for the first time.
https://isoplexis.com/

Kleo Pharmaceuticals Logo

David Spiegel, MD/PhD
Research Program: Developmental Therapeutics

Kleo Pharmaceuticals is pioneering a new class of immunotherapies utilizing small molecules to activate an individual’s own immune system to fight against cancers and infectious diseases.
http://www.kleopharmaceuticals.com/

Kolltan Logo

Joseph Schlessinger, PhD
Research Program: Signal Transduction

Celldex Therapeutics acquired Kolltan Pharmaceuticals. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.
https://www.celldex.com/

Modulate Logo

Tarek Fahmy, PhD
Research Program: Developmental Therapeutics

Modulate Therapeutics is a special purpose company created to develop one compound, IMM-01, to proof-of-concept.
https://www.tvm-lifescience.com/portfolio/modulate/

NextCure logo


Lieping Chen, MD, PhD
Research Program: Cancer Immunology

NextCure is focused on discovering and developing next generation immunotherapy-based biologics for cancer and other immune-related disorders.
https://www.nextcure.com/

Patrys logo

James Hansen, MD, MS
Research Program: Radiobiology & Radiotherapy
Peter Glazer, MD, PhD
Research Program: Radiobiology & Radiotherapy

Nucleus Therapeutics/Acquired by Patrys is focused on the development of antibody therapies for major market opportunities in the oncology area.

Omnis logo


John Rose, PhD
Research Program: Virus and Other Infection-associated Cancers

Omnis Pharmaceuticals- merged to form Vyriad and is a clinical stage biotechnology company dedicated to delivering groundbreaking virus-based therapies for cancer patients.
http://www.vyriad.com/

Osmol logo

Barbara Ehrlich, PhD
Research Program: Developmental Therapeutics

Osmol Therapeutics is developing a therapy for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) and Neurologic Impairment.
http://www.elmvc.com/project/osmol-therapeutics/

pHILip logo

Donald Engelman, PhD
Research Program: Developmental Therapeutics

pHILiP Inc. is focused on detecting, targeting, and treating acidic diseased tissue using selective insertion and folding of membrane peptides, primarily in oncology.
http://www.phlipinc.com/team/

 phytoceutica=

Yung-Chi Cheng, PhD
Research Program: Developmental Therapeutics

PhytoCeutica develops herbal therapeutics for cancer and was acquired by Kadmon Pharmaceuticals.

 onyx=

Craig Crews, PhD
Research Program: Developmental Therapeutics

Proteolix/Acquired by Onyx Pharma and develops and markets medicines for the treatment of cancer.


Gil Mor, MD, PhD, MSc
Research Program: Developmental Therapeutics

SurExam is a bio-pharmaceutical company focused on the research, development, and promotion of products related to early cancer detection.

Vedanta logo

Ruslan Medzhitov, PhD
Research Program: Cancer Immunology

Vedanta Biosciences is using its proprietary platform to discover and develop a novel class of drugs that modulate pathways of interaction between the human microbiome and the host immune system to treat disease.
https://www.vedantabio.com/

Yiviva logo

Yung-Chi Cheng, PhD
Research Program: Developmental Therapeutics

Yiviva is a biotechnology company to develop evidence-based botanical products to address aging-associated diseases.
https://yiviva.com/